Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Core Insights - Ocular Therapeutix, Inc. is participating in Clinical Trials at the Summit 2025, highlighting its commitment to advancing retinal therapies [1][4]. Company Overview - Ocular Therapeutix is a fully-integrated biopharmaceutical company focused on redefining the retina experience [4]. - The company’s investigational product AXPAXLI™ (OTX-TKI) is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [4]. - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain, and PAXTRAVA™ (OTX-TIC), which is in Phase 2 trials for open-angle glaucoma or ocular hypertension [5]. Presentation Details - Ocular will present at the Clinical Trials at the Summit 2025, with multiple sessions focused on Tyrosine Kinase Inhibitors [2][3]. - Key presentations include results from the US Phase 1 study of OTX-TKI for wet AMD and safety and efficacy data for diabetic retinopathy [6].